Ann: Phosphagenics Receives Further Arbitration Process Update, page-116

Unlike simple generic versions, Phosphagenics’ TPM®/Daptomycin product (developed in  collaboration with Agila Specialties and Mylan) has  multiple technical advantages to commercially  differentiate it from Cubicin® and other generic daptomycin competitors.  We believe this differentiation supports the potential for  significantly improved market share and revenue.  This TPM®/Daptomycin product is at present in late stage development towards a 505(b)(2) regulatory  filing in the USA.